lansoprazole has been researched along with Esophageal Hernia in 6 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty patients with complications or atypical manifestations of gastro-oesophageal reflux disease were given lansoprazole, 30 mg once daily." | 5.10 | Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2002) |
| "Posttreatment clarithromycin resistance is common in patients who do not experience success with therapy." | 2.68 | Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori. ( Axon, AT; Chalmers, DM; Dixon, MF; Langworthy, H; Moayyedi, P; Shanahan, K; Tompkins, DS, 1996) |
| "Hypogonadism has been established as a cause of osteoporosis in males, and in this case would explain the occurrence of fractures in the absence of other major risk factors." | 1.31 | Osteoporosis with underlying connective tissue disease: an unusual case. ( De Silva, M; Prasad, R, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tursi, A | 1 |
| Miwa, H | 1 |
| Haruma, K | 1 |
| Sakamoto, S | 1 |
| Sanada, K | 1 |
| Hiroi, S | 1 |
| Kinoshita, Y | 1 |
| Prasad, R | 1 |
| De Silva, M | 1 |
| Duygu, H | 1 |
| Ozerkan, F | 1 |
| Saygi, S | 1 |
| Akyüz, S | 1 |
| Moayyedi, P | 1 |
| Langworthy, H | 1 |
| Shanahan, K | 1 |
| Tompkins, DS | 1 |
| Dixon, MF | 1 |
| Chalmers, DM | 1 |
| Axon, AT | 1 |
| Frazzoni, M | 1 |
| De Micheli, E | 1 |
| Grisendi, A | 1 |
| Savarino, V | 1 |
2 trials available for lansoprazole and Esophageal Hernia
| Article | Year |
|---|---|
Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Clarithromycin; Drug Therapy | 1996 |
Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Gastro | 2002 |
4 other studies available for lansoprazole and Esophageal Hernia
| Article | Year |
|---|---|
Gitelman syndrome triggered by proton-pump inhibitor use.
Topics: Adult; Alginates; Gitelman Syndrome; Hernia, Hiatal; Humans; Lansoprazole; Male; Proton Pump Inhibit | 2019 |
Demography and treatment response in patients with predominant non-erosive reflux disease or functional dyspepsia.
Topics: Age Factors; Aged; Body Mass Index; Dyspepsia; Female; Gastroesophageal Reflux; Hernia, Hiatal; Huma | 2015 |
Osteoporosis with underlying connective tissue disease: an unusual case.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Accidental Falls; Adult; Anti-Ulcer Agents; Antibodies, Ant | 2002 |
Persistent atrial fibrillation associated with gastroesophageal reflux accompanied by hiatal hernia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Anti-Ulcer Agents; Atrial Fibri | 2008 |